Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax ® using proteome microarrays and development of recombinant protein ELISAs

Vaccine

Volumn 30, Issue 3, 2012, Pages 614-625

  Hermanson, Gary ^a   Chun, Sookhee ^b   Felgner, Jiin ^a   Tan, Xiaolin ^b   Pablo, Jozelyn ^a,b   Nakajima Sasaki, Rie ^b   Molina, Douglas M ^a   Felgner, Philip L ^b   Liang, Xiaowu ^a   Davies, D Huw ^a,b  

^a Antigen Discovery Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ELISA; Microarray; PRNT; Recombinant protein; Vaccinia virus

Indexed keywords

A13L PROTEIN; D13L PROTEIN; D8L PROTEIN; H3L PROTEIN; I1L PROTEIN; MODIFIED VACCINIA VIRUS ANKARA VACCINE; RECOMBINANT PROTEIN; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS PROTEIN; WR070 PROTEIN; WR101 PROTEIN; WR113 PROTEIN; WR118 PROTEIN; WR132 PROTEIN; WR148 PROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; PRIORITY JOURNAL; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; VACCINATION; VIRION;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PROTEIN ARRAY ANALYSIS; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY; SMALLPOX VACCINE; VACCINIA VIRUS;

EID: 84355165249     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.021     Document Type: Article

References (96)

1. Cono J., Casey C.G., Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003, 52(February (RR-4)):1-28.
2. Osborne J.D., Da Silva M., Frace A.M., Sammons S.A., Olsen-Rasmussen M., Upton C., et al. Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: the Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3. Vaccine 2007, 25(December (52)):8807-8832.
3. Nalca A., Zumbrun E.E. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther 2010, 4:71-79.
4. Handley L., Buller R.M., Frey S.E., Bellone C., Parker S. The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks. Expert Rev Vaccines 2009, 8(July (7)):841-850.
5. Mayr A., Hochstein-Mintzel V., Stickl H., Abstammung eigenschaften und verwendung des attenuierten vaccinia-stammes MVA. Infection 1975, 3:6-14.
6. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl). Zentralbl Bakteriol [B] 1978, 167(December (5-6)):375-390.
7. Carroll M.W., Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238(November (2)):198-211.
8. Meyer H., Sutter G., Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991, 72(May (Pt 5)):1031-1038.
9. Antoine G., Scheiflinger F., Dorner F., Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244(May (2)):365-396.
10. Meisinger-Henschel C., Schmidt M., Lukassen S., Linke B., Krause L., Konietzny S., et al. Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara. J Gen Virol 2007, 88(December (Pt 12)):3249-3259.
11. Meisinger-Henschel C., Spath M., Lukassen S., Wolferstatter M., Kachelriess H., Baur K., et al. Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice. J Virol 2010, 84(October (19)):9907-9919.
12. Abdalrhman I., Gurt I., Katz E. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA). Vaccine 2006, 24(May (19)):4152-4160.
13. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., et al. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428(March (6979)):182-185.
14. Hochstein-Mintzel V., Hanichen T., Huber H.C., Stickl H. [An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)]. Zentralbl Bakteriol [Orig A] 1975, 230(3):283-297.
15. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 2005, 339(September (2)):164-175.
16. Phelps A.L., Gates A.J., Hillier M., Eastaugh L., Ulaeto D.O. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 2007, 25(January (1)):34-42.
17. Stittelaar K.J., van Amerongen G., Kondova I., Kuiken T., van Lavieren R.F., Pistoor F.H., et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol 2005, 79(June (12)):7845-7851.
18. Kennedy J.S., Greenberg R.N. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines 2009, 8(January (1)):13-24.
19. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., et al. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 2001, 19(June (27)):3700-3709.
20. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006, 24(March (12)):2065-2070.
21. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992, 89(November (22)):10847-10851.
22. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996, 93(October (21)):11341-11348.
23. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum Vaccine 2009, 5(December (12)):867-871.
24. Gomez C.E., Najera J.L., Krupa M., Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 2008, 8(April (2)):97-120.
25. Rimmelzwaan G.F., Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 2009, 8(April (4)):447-454.
26. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccine 2010, 6(January (1)):78-83.
27. Hawkridge T., Scriba T.J., Gelderbloem S., Smit E., Tameris M., Moyo S., et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008, 198(August (4)):544-552.
28. Xing Z., Santosuosso M., McCormick S., Yang T.C., Millar J., Hitt M., et al. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines. Curr Gene Ther 2005, 5(October (5)):485-492.
29. Tykodi S.S., Thompson J.A. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther 2008, 8(December (12)):1947-1953.
30. Acres B., Limacher J.M., Bonnefoy J. Discovery and development of therapeutic cancer vaccines. Curr Opin Drug Discov Devel 2007, 10(March (2)):185-192.
31. Moss B. Smallpox vaccines: targets of protective immunity. Immunol Rev 2011, 239(January (1)):8-26.
32. Amanna I.J., Slifka M.K., Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006, 211(June):320-337.
33. Davies D.H., Liang X., Hernandez J.E., Randall A., Hirst S., Mu Y., et al. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA 2005, 102(January (3)):547-552.
34. Davies D.H., Molina D.M., Wrammert J., Miller J., Hirst S., Mu Y., et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics 2007, 7(May (10)):1678-1686.
35. Davies D.H., Wyatt L.S., Newman F.K., Earl P.L., Chun S., Hernandez J.E., et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 2008, 82(January (2)):652-663. PMID17977963.
36. Barbour A.G., Jasinskas A., Kayala M.A., Davies D.H., Steere A.C., Baldi P., et al. A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect Immun 2008, 76(August (8)):3374-3389. PMID18474646.
37. Crompton P.D., Kayala M.A., Traore B., Kayentao K., Ongoiba A., Weiss G.E., et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA 2010, 107(April (15)):6958-6963.
38. Doolan D.L., Mu Y., Unal B., Sundaresh S., Hirst S., Valdez C., et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 2008, 8(November (22)):4680-4694. PMID18937256.
39. Eyles J.E., Unal B., Hartley M.G., Newstead S.L., Flick-Smith H., Prior J.L., et al. Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics 2007, 7(July (13)):2172-2183. PMID: 17533643.
40. Felgner P.L., Kayala M.A., Vigil A., Burk C., Nakajima-Sasaki R., Pablo J., et al. A Burkholderia pseudomallei protein microarray reveals serodiagnostic and cross-reactive antigens. Proc Natl Acad Sci USA 2009, 106(August (32)):13499-13504.
41. Luevano M., Bernard H.U., Barrera-Saldana H.A., Trevino V., Garcia-Carranca A., Villa L.L., et al. High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays. Virology 2010, 405(September (1)):31-40.
42. Molina D.M., Pal S., Kayala M.A., Teng A., Kim P.J., Baldi P., et al. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. Vaccine 2009, (December). PMID20044059.
43. Sundaresh S., Randall A., Unal B., Petersen J.M., Belisle J.T., Gill Hartley M., et al. From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics 2007, 23(July (13)):i508-i518.
44. Vigil A., Ortega R., Nakajima-Sasaki R., Pablo J., Molina D.M., Chao C.C., et al. Genome-wide profiling of humoral immune response to Coxiella burnetii infection by protein microarray. Proteomics 2010, 10(June (12)):2259-2269.
45. Chung C.S., Chen C.H., Ho M.Y., Huang C.Y., Liao C.L., Chang W. Vaccinia virus proteome: identification of proteins in vaccinia virus intracellular mature virion particles. J Virol 2006, 80(March (5)):2127-2140.
46. Resch W., Hixson K.K., Moore R.J., Lipton M.S., Moss B. Protein composition of the vaccinia virus mature virion. Virology 2007, 358(February (1)):233-247.
47. Yoder J.D., Chen T.S., Gagnier C.R., Vemulapalli S., Maier C.S., Hruby D.E. Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol J 2006, 3:10.
48. Davies D.H., Wyatt L.S., Newman F.K., Earl P.L., Chun S., Hernandez J.E., et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax. J Virol 2008, 82(January (2)):652-663.
49. Jing L., Davies D.H., Chong T.M., Chun S., McClurkan C.L., Huang J., et al. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol 2008, 82(July (14)):7120-7134.
50. Jing L., McCaughey S.M., Davies D.H., Chong T.M., Felgner P.L., De Rosa S.C., et al. ORFeome approach to the clonal, HLA allele-specific CD4 T-cell response to a complex pathogen in humans. J Immunol Methods 2009, 347(August (1-2)):36-45.
51. Studier F.W. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif 2005, 41(May (1)):207-234.
52. Durbin B.P., Hardin J.S., Hawkins D.M., Rocke D.M. A variance-stabilizing transformation for gene-expression microarray data. Bioinformatics 2002, 18(Suppl 1):S105-S110.
53. Huber W., von Heydebreck A., Sultmann H., Poustka A., Vingron M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18(Suppl 1):S96-S104.
54. Baldi P., Hatfield G.W. DNA Microarrays and Gene Expression From Experiments to Data Analysis and Modeling 2002, Cambridge University Press.
55. Sundaresh S., Doolan D.L., Hirst S., Mu Y., Unal B., Davies D.H., et al. Identification of humoral immune responses in protein microarrays using DNA microarray data analysis techniques. Bioinformatics 2006, 22(July (14)):1760-1766.
56. Sundaresh S., Randall A., Unal B., Petersen J.M., Belisle J.T., Hartley M.G., et al. From protein microarrays to diagnostic antigen discovery: a study of the pathogen Francisella tularensis. Bioinformatics 2007, 23(July (13)):i508-i518.
57. Kreil D.P., Karp N.A., Lilley K.S. DNA microarray normalization methods can remove bias from differential protein expression analysis of 2D difference gel electrophoresis results. Bioinformatics 2004, 20(September (13)):2026-2034.
58. Baldi P., Long A.D. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics 2001, 17(June (6)):509-519.
59. Long A.D., Mangalam H.J., Chan B.Y., Tolleri L., Hatfield G.W., Baldi P. Improved statistical inference from DNA microarray data using analysis of variance and a Bayesian statistical framework. Analysis of global gene expression in Escherichia coli K12. J Biol Chem 2001, 276(June (23)):19937-19944.
60. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B 1995, 57(1):289-300.
61. Frey S.E., Newman F.K., Yan L., Lottenbach K.R., Belshe R.B. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003, 289(June (24)):3295-3299.
62. Frey S.E., Couch R.B., Tacket C.O., Treanor J.J., Wolff M., Newman F.K., et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002, 346(April (17)):1265-1274.
63. Frey S.E., Newman F.K., Kennedy J.S., Sobek V., Ennis F.A., Hill H., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007, 25(December (51)):8562-8573.
64. Sano J., Chaitman B.R., Swindle J., Frey S.E. Electrocardiography screening for cardiotoxicity after modified Vaccinia Ankara vaccination. Am J Med 2009, 122(January (1)):79-84.
65. Damon I.K., Davidson W.B., Hughes C.M., Olson V.A., Smith S.K., Holman R.C., et al. Evaluation of smallpox vaccines using variola neutralization. J Gen Virol 2009, 90(August (Pt 8)):1962-1966.
66. Amegadzie B.Y., Sisler J.R., Moss B. Frame-shift mutations within the vaccinia virus A-type inclusion protein gene. Virology 1992, 186(February (2)):777-782.
67. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) - a second-generation smallpox vaccine for biological defense. Int J Infect Dis 2004, 8(October (Suppl 2)):S31-S44.
68. Wilck M.B., Seaman M.S., Baden L.R., Walsh S.R., Grandpre L.E., Devoy C., et al. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 2010, 201(May (9)):1361-1370.
69. Seaman M.S., Wilck M.B., Baden L.R., Walsh S.R., Grandpre L.E., Devoy C., et al. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J Infect Dis 2010, 201(May (9)):1353-1360.
70. Benhnia M.R., McCausland M.M., Su H.P., Singh K., Hoffmann J., Davies D.H., et al. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J Virol 2008, 82(April (7)):3751-3768. PMID18234801.
71. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005, 11(July (7)):740-747.
72. Panchanathan V., Chaudhri G., Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand?. Immunol Cell Biol 2008, 86(January (1)):80-86.
73. Rimoin A.W., Mulembakani P.M., Johnston S.C., Lloyd Smith J.O., Kisalu N.K., Kinkela T.L., et al. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA 2010, 107(September (37)):16262-16267.
74. Hooper J.W., Custer D.M., Schmaljohn C.S., Schmaljohn A.L. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 2000, 266(January (2)):329-339.
75. Hooper J.W., Custer D.M., Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003, 306(February (1)):181-195.
76. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y., et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005, 79(September (18)):11724-11733.
77. Smith G.L., Vanderplasschen A., Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002, 83(December (Pt 12)):2915-2931.
78. Condit R.C., Moussatche N., Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res 2006, 66:31-124.
79. da Fonseca F.G., Wolffe E.J., Weisberg A., Moss B. Characterization of the vaccinia virus H3L envelope protein: topology and posttranslational membrane insertion via the C-terminal hydrophobic tail. J Virol 2000, 74(August (16)):7508-7517.
80. Lin C.L., Chung C.S., Heine H.G., Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J Virol 2000, 74(April (7)):3353-3365.
81. Hsiao J.C., Chung C.S., Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999, 73(October (10)):8750-8761.
82. Maa J.S., Rodriguez J.F., Esteban M. Structural and functional characterization of a cell surface binding protein of vaccinia virus. J Biol Chem 1990, 265(January (3)):1569-1577.
83. Niles E.G., Seto J. Vaccinia virus gene D8 encodes a virion transmembrane protein. J Virol 1988, 62(October (10)):3772-3778.
84. Berhanu A., Wilson R.L., Kirkwood-Watts D.L., King D.S., Warren T.K., Lund S.A., et al. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008, 82(April (7)):3517-3529.
85. Sakhatskyy P., Wang S., Chou T.H., Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 2006, 355(Nov (2)):164-174.
86. Salmons T., Kuhn A., Wylie F., Schleich S., Rodriguez J.R., Rodriguez D., et al. Vaccinia virus membrane proteins p8 and p16 are cotranslationally inserted into the rough endoplasmic reticulum and retained in the intermediate compartment. J Virol 1997, 71(October (10)):7404-7420.
87. Unger B., Traktman P. Vaccinia virus morphogenesis: a13 phosphoprotein is required for assembly of mature virions. J Virol 2004, 78(August (16)):8885-8901.
88. Klemperer N., Ward J., Evans E., Traktman P. The vaccinia virus I1 protein is essential for the assembly of mature virions. J Virol 1997, 71(December (12)):9285-9294.
89. Szajner P., Weisberg A.S., Lebowitz J., Heuser J., Moss B. External scaffold of spherical immature poxvirus particles is made of protein trimers, forming a honeycomb lattice. J Cell Biol 2005, 170(September (6)):971-981.
90. Funahashi S., Sato T., Shida H. Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus. J Gen Virol 1988, 69(January (Pt 1)):35-47.
91. Howard A.R., Weisberg A.S., Moss B. Congregation of orthopoxvirus virions in cytoplasmic A-type inclusions is mediated by interactions of a bridging protein (A26p) with a matrix protein (ATIp) and a virion membrane-associated protein (A27p). J Virol 2011, 84(August (15)):7592-7602.
92. Putz M.M., Midgley C.M., Law M., Smith G.L. Quantification of antibody response against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination. Nat Med 2006, 12(11):1310-1315.
93. Garcia A.D., Meseda C.A., Mayer A.E., Kumar A., Merchlinsky M., Weir J.P. Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines. Clin Vaccine Immunol 2007, 14(Aug (8)):1032-1044.
94. Fogg C., Lustig S., Whitbeck J.C., Eisenberg R.J., Cohen G.H., Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004, 78(October (19)):10230-10237.
95. Benhnia M.R., McCausland M.M., Moyron J., Laudenslager J., Granger S., Rickert S., et al. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 2009, 83(February (3)):1201-1215.
96. Thomas G., Frenzel E., Hanna H. Smallpox vaccine: non-take responses in previously vaccinated adults. Infect Control Hosp Epidemiol 2004, 25(July (7)):613-615.